Agenus to Present at the Jefferies 2015 Healthcare Conference
May 28 2015 - 10:30AM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immunology company developing
innovative treatments for cancers and other diseases, today
announced that the Company will present at the Jefferies 2015
Healthcare Conference on Thursday, June 4th at 1:00 p.m. Eastern
Time. The conference will take place at the Grand Hyatt New York in
New York City.
Webcast Information
The live and archived webcast of the presentation will be
accessible from the Company’s website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before each event to
ensure a timely connection. The archived replay will be available
on the Agenus website for one month following the conference.
About Agenus
Agenus is an immunology company developing a series of
Checkpoint Modulators for the treatment of patients with cancer,
infectious diseases, and other immune disorders, heat shock protein
(HSP)-based vaccines, and immune adjuvants. These programs are
supported by three separate technology platforms. Agenus’ internal
and partnered checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed programs. The
company’s proprietary discovery engine Retrocyte DisplayTM is
used to generate fully human and humanized therapeutic antibody
drug candidates. The Retrocyte Display platform uses a
high-throughput approach incorporating IgG format human antibody
libraries expressed in mammalian B-lineage cells. Agenus recently
acquired a powerful yeast antibody display platform termed SECANT,
developed by Celexion, LLC. SECANT allows rapid generation of
soluble, full-length human antibodies. SECANT and Agenus’ mammalian
antibody display platform have complementary strengths and further
bolster Agenus' abilities to generate and optimize fully human
monoclonal antibodies. Agenus’ heat shock protein-based vaccines
have completed Phase 2 studies in newly diagnosed glioblastoma
multiforme, and in the treatment of herpes simplex viral infection;
the heat shock protein-based vaccine platform can generate
personalized as well as off the shelf products. The company’s QS-21
Stimulon® adjuvant platform is extensively partnered with
GlaxoSmithKline and with Janssen Sciences Ireland UC and includes
several candidates in Phase 2 trials, as well as shingles and
malaria vaccines which have successfully completed Phase 3 clinical
trials.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding the Company’s upcoming corporate
presentation. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission for the period ended March 31, 2015. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150528006076/en/
Media:BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney/Jamie Maarten,
212-600-1902andrea@argotpartners.comjamie@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2023 to May 2024